|Orexigen Will Report Phase 3 Contrave Results on Monday, July 20 (Pre-Market)|
|Friday, 17 July 2009 16:22|
SAN DIEGO-- Orexigen Therapeutics, Inc. (NASDAQ:OREX), a biopharmaceutical company focused on the treatment of obesity, plans to announce the results of the three remaining Phase 3 clinical trials in the Contrave program on Monday, July 20, 2009 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time.
Orexigen management will host the call and webcast to discuss the results of these clinical trials and answer questions. The live call may be accessed by phone by calling 1-800-561-2813 (domestic) or 617-614-3529 (international), participant code 14007929. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com, and will be archived for 14 days following the call.
Below is the BioMedReports.com FDA Calendar entry for OREX:
OREX has three pending Phase 3 clinical trials for its experimental weight loss drug Contrave (naltrexone + bupropion), with results expected during 3Q09 based on guidance provided on 5/7/09 with quarterly operating results. The Company’s first Phase 3 trial to be completed (results were released in January 2009), NB-302, was designed to demonstrate the benefits of Contrave therapy when added to an intensive, physician-directed exercise and diet program. The NB-301 and NB-303 trials were designed to demonstrate the benefits of Contrave in a more typical setting of diet and exercise. Finally, the NB-304 trial was designed to assess the benefit of Contrave in an obese population with co-morbid type 2 diabetes.